Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
GNLX
GNLX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
GNLX News
Genelux Corporation to Host Virtual Fireside Chat on January 19, 2026
Jan 12 2026
Yahoo Finance
ScinoPharm Secures FDA Approval for Glatiramer Acetate Injection in Multiple Sclerosis
Jan 09 2026
NASDAQ.COM
Genelux Prices 6.67M Share Offering at $3.00, Raising $20M
Jan 08 2026
Globenewswire
Alumis Inc. (ALMS) Shares Surge 17.33% on Phase 3 Clinical Trial Data Announcement
Jan 06 2026
NASDAQ.COM
Genelux Reports Promising Interim Results for Olvi-Vec in Lung Cancer Trials
Jan 05 2026
NASDAQ.COM
Genelux Appoints Jason Litten as CMO to Advance Olvi-Vec Development
Jan 02 2026
NASDAQ.COM
Genelux Appoints Dr. Jason Litten as CMO to Advance Olvi-Vec Clinical Development
Jan 02 2026
Globenewswire
Genelux Appoints Dr. Jason Litten as CMO to Advance Olvi-Vec Development
Jan 02 2026
Newsfilter
Genelux CEO to Participate in Piper Sandler Healthcare Conference, Showcasing New Therapy Progress
Nov 26 2025
Globenewswire
Genelux Corporation Announces Financial Results for Q3 2025 and Shares Business Updates
Nov 05 2025
Newsfilter
Lake Street Begins Coverage of Genelux with a Buy Rating and Sets Price Target at $16
Oct 21 2025
Benzinga
Biotech Stocks Surge After Hours: Insider Purchases, Trial Progress, and Strategic Partnerships Drive Growth
Sep 11 2025
NASDAQ.COM
LUCID CAPITAL MARKETS Initiates Coverage On Genelux with Buy Rating, Announces Price Target of $10
Jul 21 2025
Benzinga
Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference
May 01 2025
Newsfilter
HC Wainwright & Co. Reiterates Buy on Genelux, Maintains $30 Price Target
Mar 31 2025
Benzinga
Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Mar 28 2025
Newsfilter
Show More News
